Corbus Pharmaceuticals Nears Key Obesity Drug Data Readout — Corbus Pharmaceuticals Holdings, Inc.

Event summary

Corbus Pharmaceuticals completed last patient visit in CANYON-1 Phase 1b trial of obesity drug CRB-913.
Topline data from the 240-patient dose-finding study expected in September 2026.
CRB-913 is a once-daily oral CB1 inverse agonist designed as an alternative to GLP-1 therapies.
Phase 1a results showed promising weight loss with favorable GI tolerability profile.

The big picture

Corbus Pharmaceuticals is positioning CRB-913 as an orthogonal approach to weight management, addressing significant gaps in current GLP-1 therapies where over 60% of patients discontinue treatment within a year. The upcoming data readout will be critical in determining whether this once-daily oral therapy can compete with established obesity treatments and capture market share in this rapidly growing therapeutic area.

What we're watching

Clinical Efficacy: Whether CRB-913 can demonstrate superior weight loss results compared to existing GLP-1 therapies.
Safety Profile: How the drug's GI tolerability and neuropsychiatric safety compare to historical CB1 inverse agonists.
Market Differentiation: The potential for CRB-913 to establish itself as a non-incretin alternative in the obesity treatment landscape.